Disclosure: I’m participating in the Break Up with Your Makeup Blogger Contest Sponsored by Galderma Laboratories, L.P.
Rosacea is a treatable, chronic inflammatory skin condition and one of the most common symptoms is persistent facial redness and sometimes acne-like bumps . It’s estimated that 16MM Americans are affected by the condition. As I’ve aged, I have developed a mild case of rosacea mostly on my cheeks and chin. It’s tempting to cover it up with layers of makeup but I want my skin to breathe and detest the look of makeup that looks like it was applied with a trowel for cement. Cetaphil products have helped keep my mild rosacea under control.
Rosacea CAN be successfully treated. Mivaso® (brimonidine) is an FDA-approved topical gel, and one of the first prescription treatment product developed specifically to treat the persistent redness associated with Rosacea. It calms redness for up to 12 hours. With treatment, you can get away from caking on the makeup and back to a fresh natural face. Sounds perfect, right?
Wait….there’s more! Mivaso is offering a Cetaphil gift basket to one lucky Prime Beauty reader! Just leave me a comment and tell me if you have experienced rosacea and what you do to treat and/or prevent it. Good luck!
a Rafflecopter giveaway
But wait…that’s not all… Mirvaso is hosting a sweepstakes to raise awareness and to encourage people to “Break Up with Your Makeup.” Not only will you look red-carpet worthy, but YOU have a chance to join the party. SEE BELOW TO ENTER TO WIN A TRIP TO THE EMMYS! Good luck!
Important Safety Information
Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.